Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real‐World Evidence From an International Collaborative Database
Journal of Diabetes Research · 2024-01 · 2024 (1)
DOI: 10.1155/2024/3470654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, online erschienen am 30.05.2024. Verfasst von Matthew Anson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes & Endocrinology Research and Pain Research Institute Institute of Life Course and Medical Sciences University of Liverpool and Liverpool Uni…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Drug Therapy, Combination, Metformin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Information Systems Committee.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
We compared the glycaemic and cardiorenal effects of combination therapy involving metformin, pioglitazone, sodium‐glucose‐linked‐cotransporter‐2 inhibitor (SGLT2i), and glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) versus a more conventional glucocentric treatment approach combining sulphonylureas (SU) and insulin from the point of type 2 diabetes (T2D) diagnosis.
Methods
We performed a retrospective cohort study using the Global Collaborative Network in TriNetX. We included individuals prescribed metformin, pioglitazone, an SGLT2i, and a GLP‐1 RA for at least 1‐year duration, within 3 years of a T2D diagnosis, and compared with individuals prescribed insulin and a SU within the same temporal pattern. Individuals were followed up for 3 years.
Results
We propensity score‐matched (PSM) for 26 variables. A total of 1762 individuals were included in the final analysis ( n = 881 per cohort). At 3‐years, compared to the insulin/SU group, the metformin/pioglitazone/SGLT2i/GLP‐1 RA group had a lower risk of heart failure (HR 0.34, 95% CI 0.13–0.87, p = 0.018), acute coronary syndrome (HR 0.29, 95% CI 0.12–0.67, p = 0.002), stroke (HR 0.17, 95% CI 0.06–0.49, p < 0.001), chronic kidney disease (HR 0.50, 95% CI 0.25–0.99, p = 0.042), and hospitalisation (HR 0.59, 95% CI 0.46–0.77, p < 0.001).
Conclusions
In this real‐world study, early, intensive polytherapy, targeting the distinct pathophysiological defects in T2D, is associated with significantly more favourable cardiorenal outcomes, compared to insulin and SU therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes & Endocrinology Research and Pain Research Institute Institute of Life Course and Medical Sciences University of Liverpool and Liverpool University Hospital NHS Foundation Trust, LiverpoolUK.
- School of Medicine Barts and the London Queen Mary University of London, LondonUK.
- Centre for Musculoskeletal Research Division of Musculoskeletal and Dermatological Science School of Biological Sciences Faculty of Biological Medicine and Health The University of Manchester Manchester Academic Health…
- TriNetX LLC, Cambridge, MassachusettsUSA.
- UCL Institute for Global Health University College London, LondonUK.
- Diabetes & Endocrinology Research Institute of Life Course and Medical Sciences University of Liverpool and Liverpool University Hospital NHS Foundation Trust, LiverpoolUK.
ORCID-Profile: Matthew Anson, Sizheng S Zhao, Shabbar Jaffar, Anupam Garrib, Uazman Alam
Förderung
- Joint Information Systems Committee
Zitieren
APA
Anson, M., Malik, A., Zhao, S. S., Austin, P., Ibarburu, G. H., Jaffar, S., Garrib, A., Cuthbertson, D. J., & Alam, U. (2024). Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real‐World Evidence From an International Collaborative Database. Journal of Diabetes Research, 2024(1). https://doi.org/10.1155/2024/3470654
Vancouver
Anson M, Malik A, Zhao SS, Austin P, Ibarburu GH, Jaffar S, et al. Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real‐World Evidence From an International Collaborative Database. Journal of Diabetes Research. 2024;2024(1). doi:10.1155/2024/3470654
BibTeX
@article{Anson2024,
author = {Anson, Matthew and Malik, Ayesha and Zhao, Sizheng S and Austin, Philip and Ibarburu, Gema H and Jaffar, Shabbar and Garrib, Anupam and Cuthbertson, Daniel J and Alam, Uazman},
title = {Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real‐World Evidence From an International Collaborative Database},
journal = {Journal of Diabetes Research},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/3470654}
}
EUVIMED